Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation

Leona A. Holmberg, Michael Boeckh, Heather Hooper, Wendy Leisenring, Scott Rowley, Shelly Heimfeld, Oliver Press, David G. Maloney, Peter McSweeney, Lawrence Corey, Richard Maziarz, Frederick R. Appelbaum, William Bensinger

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.

Original languageEnglish (US)
Pages (from-to)4029-4035
Number of pages7
JournalBlood
Volume94
Issue number12
StatePublished - Dec 15 1999
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Stem cells
Cytomegalovirus
Blood
Incidence
Grafts
Regression analysis
Transplants
Logistics
Tumors
Contamination
Therapeutics
Cells
Logistic Models
Regression Analysis
Peripheral Blood Stem Cells
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Holmberg, L. A., Boeckh, M., Hooper, H., Leisenring, W., Rowley, S., Heimfeld, S., ... Bensinger, W. (1999). Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation. Blood, 94(12), 4029-4035.

Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation. / Holmberg, Leona A.; Boeckh, Michael; Hooper, Heather; Leisenring, Wendy; Rowley, Scott; Heimfeld, Shelly; Press, Oliver; Maloney, David G.; McSweeney, Peter; Corey, Lawrence; Maziarz, Richard; Appelbaum, Frederick R.; Bensinger, William.

In: Blood, Vol. 94, No. 12, 15.12.1999, p. 4029-4035.

Research output: Contribution to journalArticle

Holmberg, LA, Boeckh, M, Hooper, H, Leisenring, W, Rowley, S, Heimfeld, S, Press, O, Maloney, DG, McSweeney, P, Corey, L, Maziarz, R, Appelbaum, FR & Bensinger, W 1999, 'Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation', Blood, vol. 94, no. 12, pp. 4029-4035.
Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S et al. Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation. Blood. 1999 Dec 15;94(12):4029-4035.
Holmberg, Leona A. ; Boeckh, Michael ; Hooper, Heather ; Leisenring, Wendy ; Rowley, Scott ; Heimfeld, Shelly ; Press, Oliver ; Maloney, David G. ; McSweeney, Peter ; Corey, Lawrence ; Maziarz, Richard ; Appelbaum, Frederick R. ; Bensinger, William. / Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation. In: Blood. 1999 ; Vol. 94, No. 12. pp. 4029-4035.
@article{7342be8ce8334f729d49f4e9ef516fc2,
title = "Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation",
abstract = "High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6{\%}) developed CMV disease and 4 patients (12.9{\%}) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2{\%}) developed CMV disease, with 5 deaths (2.1{\%}). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.",
author = "Holmberg, {Leona A.} and Michael Boeckh and Heather Hooper and Wendy Leisenring and Scott Rowley and Shelly Heimfeld and Oliver Press and Maloney, {David G.} and Peter McSweeney and Lawrence Corey and Richard Maziarz and Appelbaum, {Frederick R.} and William Bensinger",
year = "1999",
month = "12",
day = "15",
language = "English (US)",
volume = "94",
pages = "4029--4035",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation

AU - Holmberg, Leona A.

AU - Boeckh, Michael

AU - Hooper, Heather

AU - Leisenring, Wendy

AU - Rowley, Scott

AU - Heimfeld, Shelly

AU - Press, Oliver

AU - Maloney, David G.

AU - McSweeney, Peter

AU - Corey, Lawrence

AU - Maziarz, Richard

AU - Appelbaum, Frederick R.

AU - Bensinger, William

PY - 1999/12/15

Y1 - 1999/12/15

N2 - High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.

AB - High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.

UR - http://www.scopus.com/inward/record.url?scp=13044276241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13044276241&partnerID=8YFLogxK

M3 - Article

C2 - 10590046

AN - SCOPUS:13044276241

VL - 94

SP - 4029

EP - 4035

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -